Halozyme Therapeutics Inc (HALO)

04:07 AM

Halozyme Therapeutics Inc. Stock Analysis and ForecastPowerful profit generation - jammulinksnews.com

04:07 AM

Jul 21, 2025

What analysts say about Halozyme Therapeutics Inc. stockExceptional profit margins - Autocar Professional

Jul 21, 2025

Jul 20, 2025

Is Halozyme Therapeutics Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com

Jul 20, 2025

Jul 20, 2025

What drives Halozyme Therapeutics Inc. stock priceExplosive capital gains - jammulinksnews.com

Jul 20, 2025

Jul 17, 2025

Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Jul 17, 2025

Jul 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $60.00 - MarketBeat

Jul 16, 2025

Jul 16, 2025

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance

Jul 16, 2025

Jul 16, 2025

How Halozyme Therapeutics Inc. stock performs during market volatilityFree AI-Powered Stock Predictions - beatles.ru

Jul 16, 2025

Jul 16, 2025

Halozyme Therapeutics: A 20% CAGR Growth Story Powered by ENHANZE, Litigation Upside, and Undervalued M&A Potential - AInvest

Jul 16, 2025

Jul 16, 2025

Halozyme Therapeutics' strategic adoption - MarketScreener

Jul 16, 2025

Jul 14, 2025

Halozyme Therapeutics (HALO): Navigating Regulatory Crosscurrents to Seize Long-Term Value - AInvest

Jul 14, 2025

Jul 14, 2025

Halozyme Therapeutics Downgraded Amid Concerns Over Long-Term Value. - AInvest

Jul 14, 2025

Jul 14, 2025

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) (HALO) - Seeking Alpha

Jul 14, 2025

Jul 11, 2025

Halozyme Therapeutics: CEO Stock Sales vs. Robust Pipeline and Financial Momentum - AInvest

Jul 11, 2025

Jul 10, 2025

Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises By Investing.com - Investing.com South Africa

Jul 10, 2025

Jul 10, 2025

Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises - Investing.com Nigeria

Jul 10, 2025

Jul 10, 2025

Halozyme stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com Canada

Jul 10, 2025

Jul 10, 2025

Goldman Sachs Resumes Coverage of Halozyme (HALO) with Neutral R - GuruFocus

Jul 10, 2025

Jul 07, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga

Jul 07, 2025

Jul 06, 2025

Halozyme Therapeutics Added to Russell 1000® Index - Eastern Progress

Jul 06, 2025

Jul 04, 2025

Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday - MSN

Jul 04, 2025

Jul 04, 2025

Halozyme Therapeutics (HALO): A Momentum Stock to Consider - AInvest

Jul 04, 2025

Jul 03, 2025

Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance

Jul 03, 2025

Jul 01, 2025

Halozyme Therapeutics Added to Russell 1000® Index | HALO Stock News - GuruFocus

Jul 01, 2025

Jul 01, 2025

Halozyme Therapeutics: A Catalyst-Fueled Ascension to the Russell 1000 - AInvest

Jul 01, 2025

Jun 30, 2025

Halozyme therapeutics added to Russell 1000 index By Investing.com - Investing.com South Africa

Jun 30, 2025

Jun 30, 2025

Halozyme therapeutics added to Russell 1000 index - Investing.com

Jun 30, 2025

Jun 21, 2025

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve

Jun 21, 2025

Jun 20, 2025

Breakthrough for CIDP Patients: EU Green Lights First Novel Treatment in 3 DecadesHalozyme Partnership Delivers - Stock Titan

Jun 20, 2025

Jun 18, 2025

Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media

Jun 18, 2025

Jun 18, 2025

Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st

Jun 18, 2025

Jun 16, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance

Jun 16, 2025

Jun 15, 2025

Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha

Jun 15, 2025

Jun 12, 2025

Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga

Jun 12, 2025

Jun 12, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

Jun 12, 2025

Jun 11, 2025

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN

Jun 11, 2025

Jun 10, 2025

TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada

Jun 10, 2025

Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com

Jun 09, 2025

Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria

Jun 09, 2025

Jun 09, 2025

Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025

Jun 06, 2025

Merck gains U.S. patent office support in Keytruda dispute - MSN

Jun 06, 2025

Jun 05, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com

Jun 05, 2025

Jun 05, 2025

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025